1. Home
  2. QURE vs COLL Comparison

QURE vs COLL Comparison

Compare QURE & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uniQure N.V.

QURE

uniQure N.V.

HOLD

Current Price

$46.70

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$33.70

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QURE
COLL
Founded
1998
2002
Country
Netherlands
United States
Employees
248
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
QURE
COLL
Price
$46.70
$33.70
Analyst Decision
Buy
Strong Buy
Analyst Count
14
5
Target Price
$45.00
$51.40
AVG Volume (30 Days)
2.0M
324.8K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
29.67
N/A
EPS
N/A
0.40
Revenue
$13,107,000.00
$780,567,000.00
Revenue This Year
$126.12
$8.01
Revenue Next Year
$200.43
N/A
P/E Ratio
N/A
$83.35
Revenue Growth
N/A
23.62
52 Week Low
$8.73
$29.19
52 Week High
$71.50
$50.79

Technical Indicators

Market Signals
Indicator
QURE
COLL
Relative Strength Index (RSI) 79.16 47.77
Support Level $21.63 $31.20
Resistance Level $60.70 $35.86
Average True Range (ATR) 2.43 1.32
MACD 1.72 0.13
Stochastic Oscillator 84.49 63.27

Price Performance

Historical Comparison
QURE
COLL

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: